I am a 63-year-old psychologist, clinician, professor, and poster child for multiple sclerosis (MS). After more than 30 years with the disease, I’m still mobile, sometimes with a cane. My speech isn’t impaired, though my volume is, and my memory is taking a nosedive. I have no working taste…
Read more
Tyruko (natalizumab-sztn) is now commercially available in the U.S. as the first and only approved biosimilar to Tysabri for adults with relapsing forms of multiple sclerosis (MS). The therapy received approval from the U.S. Food and Drug Administration (FDA) in 2023 for all indications covered by the…
A clinical trial is now recruiting participants to test whether an experimental vaccine for the Epstein-Barr virus (EBV) is safe and may help reduce disease activity in people with multiple sclerosis (MS). The Phase 2 study (NCT06735248) aims to enroll 180 adults, ages 18 to 55, with…
Multiple sclerosis (MS) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) share similar symptoms but are two biologically distinct conditions, with different immune signatures, a study found. These findings help explain why treatments approved for MS generally show limited effectiveness for MOGAD, researchers said. “These findings support MOGAD as its…
November feels like an inhale that hasn’t yet decided whether to sigh or sing. The mornings are quieter now, the air cooler, and for the first time in months, I also feel more peaceful. On the other side of a recent relapse with relapsing-remitting multiple sclerosis, facing…
Get regular updates to your inbox.
